Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy
Open Access
- 30 November 2023
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 9 (1) , 223-235
Abstract
Objective: Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy. For this reason, we explored the effects of cenobamate on cognitive performance, as well as on negative affectivity and quality of life in a sample of patients with drug‐resistant epilepsy.Methods: Two prospective cohort studies were carried out. In Study 1, 32 patients (22 men and 10 women) underwent a baseline (T0) and a short‐term (T1) neuropsychological assessment after 3 months of cenobamate administration. In Study 2, 22 patients (16 men and 6 women) from the T1 sample also underwent a baseline and a follow‐up evaluation (T2) 6 months after T0.Results: No significant differences were found in cognitive variables, negative affectivity, and quality of life either in Study 1 or Study 2. Similarly, based on the reliable change index, it was found that most patients showed no changes in these variables.Significance: These results suggest that cenobamate is a safe antiseizure medication in terms of cognition, negative affectivity, or quality of life since no adverse events have been found after 3 and 6 months of treatment.Plain Language Summary: Cenobamate is a new antiseizure medication. In patients with epilepsy, cenobamate seems to not affect cognition, anxiety, depression, or quality of life.Keywords
Funding Information
- Generalitat Valenciana (ACIF/2021/094)
This publication has 33 references indexed in Scilit:
- Current standards of neuropsychological assessment in epilepsy surgery centers across EuropeEpilepsia, 2017
- The effect of quantitative and qualitative antiepileptic drug changes on cognitive recovery after epilepsy surgerySeizure: European Journal of Epilepsy, 2016
- Adverse cognitive effects of antiepileptic pharmacotherapy: Each additional drug mattersEuropean Neuropsychopharmacology, 2015
- Depression and Anxiety in People with EpilepsyJournal of Clinical Neurology, 2014
- Reliable Change on the Boston Naming TestJournal of the International Neuropsychological Society, 2012
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- EpiTrack: Tracking cognitive side effects of medication on attention and executive functions in patients with epilepsyEpilepsy & Behavior, 2005
- Cognitive Decline in Severe Intractable EpilepsyEpilepsia, 2005
- Naming ability after tailored left temporal resection with extraoperative language mapping: Increased risk of decline with later epilepsy onset ageEpilepsy & Behavior, 2005
- Antiepileptic drugs and memoryEpilepsy & Behavior, 2004